Throughout this process I have been extremely impressed by the skill and professionalism of Ockham's employees, the quality services they deliver, and the vision of the leadership team. James Esinhart commented: "This merger is a natural progression towards our strategic goal of becoming the premier specialized mid-tier CRO. The combined company's clients will benefit from a fuller range of services across a global network of offices and expertise.Ĭhiltern CEO Dr. Global Functional Service Provider (FSP)/Sourcing provision specializing in tailored resourcing solutions across clinical, regulatory, medical and biometrics (Chiltern Source).Biopharmaceutical services with global reach and scale, including deep therapeutic experience in respiratory, ophthalmology, infectious disease, vaccines and dermatology (Chiltern Biopharmaceutics) and.Oncology specialization with extensive expertise across all clinical phases of development (Chiltern Oncology).This complementary transaction significantly strengthens the combined service offerings in three strategic areas: Baker, becoming Chief Development Officer. Chiltern's CEO Jim Esinhart, PhD will be CEO of the Chiltern Group, with Ockham's CEO, James V. Ockham's management team will join the management of the enlarged group, thus ensuring a seamless continuation of high quality services. The combined company will be called Chiltern. and CARY, N.C., J/PRNewswire/ - Chiltern and Ockham, two leading full-service contract research organizations (CROs), today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.
0 kommentar(er)
